Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Women's sexual function and dysfunction: current uncertainties, future directions

International Journal of Impotence Research volume 20, pages 466–478 (2008)Cite this article

Abstract

There is increasing evidence that women at the outset of sexual activity do not need to have sexual desire, as in ‘drive’, and that many do not distinguish desire from arousal. Multiple modes of investigation confirm poor correlation between women's subjective arousal and measured genital congestion. Suggested revisions to the DSM-IV definitions of sexual disorder have been published: there is now need to align interview assessments and screening questionnaires with contemporary understanding of women's sexual response. Whereas the psychological factors associated with women's sexual function and resilience to biological insults and external stressors are well documented, the role of biological factors is less clear. Variations in the rate of decline of adrenal and ovarian pro-hormones, activity of converting enzymes in peripheral cells, sensitivity of androgen and estrogen receptors and cerebral production of sex steroids may all be involved. Thus there is great complexity underlying the question of sex hormone supplementation, and in particular, little clarity as to which women have decreased brain and/or peripheral androgen activity. When psychosexual etiological factors appear to be minimal and investigational testosterone supplementation is considered, it would be appropriate to target women with disordered arousal and desire in keeping with the recently recommended revised definitions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Dennerstein L, Dudley E, Burger H . Are changes in sexual functioning during mid-life due to aging or menopause. Fertil Steril 2001; 76: 456–460.

    CAS  PubMed  Google Scholar 

  2. Caine VS, Johannes CB, Avis NE, Mohr B, Schocken M, Skurnick J et al. Sexual functioning and practices in a multi-ethnic study of midlife woman: baseline results from SWAN. J Sex Res 2003; 40: 266–276.

    Google Scholar 

  3. Meston CM, Buss DM . Why humans have sex. Arch Sex Behav 2007; 36: 477–507.

    PubMed  Google Scholar 

  4. McCall K, Meston C . Differences between pre and postmenopausal women in cues for sexual desire. J Sex Med 2007; 4: 364–371.

    PubMed  Google Scholar 

  5. Klusmann D . Sexual motivation and the duration of partnership. Arch Sex Behav 2002; 31: 275–287.

    PubMed  Google Scholar 

  6. Ganz PA, Greendale GA . Female sexual desire—beyond testosterone. J Nat Cancer Inst 2007; 99: 659–661.

    CAS  PubMed  Google Scholar 

  7. Sidi H, Naing L, Midin H, Rusvanei N, Jaafar N . The female sexual response cycle: do Malaysian women conform to the circular model. J Sex Med; doi:10.1111/j.1743-6109.2007.00653.x.

    PubMed  Google Scholar 

  8. Althof SE, Dean J, Derogates LR, Rosen RC, Sisson M . Current perspectives on the clinical assessment and diagnosis of female sexual dysfunction and clinical studies of potential therapies: statement of concern. J Sex Med 2005; 2S3: 146–153.

    Google Scholar 

  9. Sand M, Fisher WA . Women's endorsement of models of female sexual response: the nurses' sexuality study. J Sex Med 2007; 4: 708–719.

    PubMed  Google Scholar 

  10. Graham CA, Sanders SA, Milhausen RR, McBride KR . Turning on and turning off: a focus group study of the factors that affect women's sexual arousal. Arch Sex Behav 2004; 33: 527–538.

    PubMed  Google Scholar 

  11. Brotto LA, Heiman JR, Tolman D . Toward conceptualizing sexual desire in middle-aged women. J Sex Res (in press).

  12. Karama S, Lecours AR, Leroux JM, Bourgouin P, Beaudoin G, Joubert S et al. Areas of brain activation in males and females during viewing of erotic film excerpts. Hum Brain Mapp 2002; 16: 1–13.

    PubMed  PubMed Central  Google Scholar 

  13. Georgiadis JR, Kortekaas R, Kuipers R, Nieuwenburg A, Pruin J, Simone Reinders et al. Regional cerebral flood flow changes associated with clitorally-induced orgasm in healthy women. Eur J Neurosci 2006; 24: 3305–3316.

    PubMed  Google Scholar 

  14. van Lunsen RHW, Laan E . Genital vascular responsiveness and sexual feelings in midlife women: psychophysiologic, brain and genital imaging studies. Menopause 2004; 11: 741–748.

    PubMed  Google Scholar 

  15. Maravilla KR, Cao Y, Heiman JR . Serial MR imaging with MS-325 for evaluating female sexual arousal response: determination of intra-subjective reproducibility. J Magn Reson Imaging 2003; 18: 216–224.

    PubMed  Google Scholar 

  16. Chivers ML, Bailey JM . A sex difference in features that elicit genital response. Biol Psychol 2005; 70: 115–120.

    PubMed  Google Scholar 

  17. Diagnostic and Statistical Manual of Mental Disorders-IV-TR. American Psychiatric Association: Washington, DC, 2003.

  18. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K et al. Definitions of women's sexual dysfunctions reconsidered: advocating expansion and revision. J Psychosom Obstet Gynaecol 2003; 24: 221–229.

    CAS  PubMed  Google Scholar 

  19. Segraves R, Balon R, Clayton A . Proposal for changes in diagnostic criteria for sexual dysfunctions. J Sex Med 2007; 4: 567–580.

    PubMed  Google Scholar 

  20. Basson R . Using a different model for female sexual response to address women's problematic low sexual desire. J Sex Marital Ther 2001; 27: 395–403.

    CAS  PubMed  Google Scholar 

  21. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC . Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006; 13: 46–56.

    PubMed  Google Scholar 

  22. Dennerstein L, Koochaki P, Barton I, Graziottin A . Hypoactive sexual desire disorder in menopausal women: a survey of western European women. J Sex Med 2006; 3: 212–222.

    PubMed  Google Scholar 

  23. Hartmann U, Philippsohn S, Heiser K, Rüffer-Hesse C . Low desire in mid life and older women: personality factors, psychosocial development, present sexuality. Menopause 2004; 11: 726–740.

    PubMed  Google Scholar 

  24. King M, Holt V, Nazareth I . Women's view of their sexual difficulties: agreement and disagreement for the clinical diagnoses. Arch Sex Behav 2007; 36: 281–288.

    PubMed  Google Scholar 

  25. Tiefer L . A new view of women's sexual problems: why new? Why now? J Sex Res 2001; 38: 89–96.

    Google Scholar 

  26. Brotto LA, Basson R, Luria M . A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med 2008; doi:10.1111/j.1743-6109.2008.00850.x, 23 May 2008.

    PubMed  Google Scholar 

  27. Basson R, Brotto LA . Sexual psychophysiology and effects of sildenafil citrate in estrogenized women with acquired genital arousal disorder and impaired orgasm: a randomized controlled trial. Brit J Obstet Gynecol 2003; 110: 1014–1024.

    CAS  Google Scholar 

  28. Leiblum SR, Chivers ML . Normal and persistent genital arousal in women: new perspectives. J Sex Marital Ther 2007; 33: 357–373.

    PubMed  Google Scholar 

  29. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ . The study of sexuality and health among older adults in the United States. New Engl Med 2007; 357: 762–774.

    CAS  Google Scholar 

  30. Dunn KM, Croft PR, Hackett GI . Association of sexual problems with social, psychological, and physical problems in men and women: a cross-sectional population survey. J Epidemiol Community Health 1999; 53: 144–148.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Bancroft J, Loftus J, Long JS . Distress about sex: a national survey of women in heterosexual relationships. Arch Sex Behav 2003; 32: 193–211.

    PubMed  Google Scholar 

  32. Cyranowski JM, Bromberge J, Youk A, Matthews K, Kravitz HM, Powell LH . Lifetime depression history and sexual function in women at midlife. Arch Sex Behav 2004; 33: 539–548.

    PubMed  Google Scholar 

  33. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M . Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4: 917–929.

    CAS  PubMed  Google Scholar 

  34. Enzlin P, Mathieu C, Van den Bruel A, Bosteels J, van der Schueren D, Demyttenaere K . Sexual dysfunction in women with type I diabetes. Diabetes Care 2002; 25: 672–677.

    PubMed  Google Scholar 

  35. Soykan A, Boztas H, Kutlay S, Ince E, Nergizoglu G, Dileköz AY et al. Do sexual dysfunctions get better during dialysis? Results of a six-month prospective follow-up study from Turkey. Int J Impot Res 2005; 17: 359–363.

    CAS  PubMed  Google Scholar 

  36. Zivadinov R, Zorzon M, Locatelli L, Stival B, Monti F, Nasuelli D et al. Sexual dysfunction in multiple sclerosis: a MRI neurophysiological and urodynamic study. J Neurol Sci 2003; 210: 73–76.

    PubMed  Google Scholar 

  37. Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA . Correlates of sexual function among multi ethnic middle aged women: results from the study of women's health across the nation (SWAN). Menopause 2005; 12: 385–398.

    PubMed  Google Scholar 

  38. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E et al. Sexual problems among women and men, aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviours. Int J Impot Res 2005; 17: 39–57.

    CAS  PubMed  Google Scholar 

  39. Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH . Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999; 17: 2371–2380.

    CAS  PubMed  Google Scholar 

  40. Cayan S, Bozlu M, Canpolat B, Akbay E . The assessment of sexual functions in women with male partners complaining of erectile dysfunction: does treatment of male sexual dysfunction improve female partner's sexual functions? J Sex Marital Ther 2004; 30: 333–341.

    PubMed  Google Scholar 

  41. Öberg K, Sjögern Fugl Myer K . On Swedish women's distressing sexual dysfunctions: some concomitant conditions and life satisfaction. J Sex Med 2005; 2: 169–180.

    PubMed  Google Scholar 

  42. Freedman MA . Estrogen, vaginal pH, and genital atrophy. Menopause 2006; 13: S11–S987.

    Google Scholar 

  43. Valadares ALR, Pinto Neto AM, Osis MJD, Sousa MH, Costa-Paiva LHS . Dyspareunia: a population based study with Brazilian women between 40 and 65 years old. Menopause 2006; 13: P-98–P-1016.

    Google Scholar 

  44. Aziz A, Brannstrom M, Bergquist C, Silfverstolpe G . Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005; 83: 1021–1028.

    PubMed  Google Scholar 

  45. Farquar CM, Harvey SA, Yu Y, Sadler L, Stewart EW . A prospective study of three years of outcomes after hysterectomy with and without oophorectomy. Obstet Gynecol 2006; 194: 714–717.

    Google Scholar 

  46. Teplin V, Vittinghoff E, Lin F, Learman LA, Richter HE, Kuppermann M . Oophorectomy in premenopausal women: health-related quality of life and sexual functioning. Obstet Gynecol 2007; 109: 347–354.

    PubMed  Google Scholar 

  47. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ . Ovarian androgen production in post menopausal women. J Clin Endocrinol Metab 2007; 92: 3040–3304.

    CAS  PubMed  Google Scholar 

  48. Labrie F, Bélanger A, Tusan L, Cusan L, Candas B . Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997; 82: 2396–2402.

    CAS  PubMed  Google Scholar 

  49. Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L et al. Androgen Glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem 2006; 99: 182–188.

    CAS  Google Scholar 

  50. Palacios S . Androgens and female sexual function. Maturitas 2007; 57: 61–65.

    CAS  PubMed  Google Scholar 

  51. Santoro A, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB et al. Correlates of circulating androgens in midlife women: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2005; 90: 2004–2063.

    Google Scholar 

  52. Davis SR, Davison SL, Donath S, Bell RJ . Circulating androgen levels in self-reported sexual function in women. JAMA 2005; 294: 91–96.

    CAS  PubMed  Google Scholar 

  53. van der Stege JG, Groen H, van Zadelhoff SJN, Lambalk CB, Braat DDM, van Kasteren YM et al. Decreased androgen concentrations and diminished general and sexual wellbeing in women with premature ovarian failure. Menopause 2008; 15: 23–31.

    PubMed  Google Scholar 

  54. Woods NF, Sullivan Mitchell E, Tao Y, Viernes HA, Stapleton PL, Farin FM . Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Menopause 2006; 13: 902–910.

    PubMed  Google Scholar 

  55. Melcangi RC, Panzica GC . Neuroactive steroids: old players in a new game. Neuroscience 2006; 138: 733–739.

    CAS  PubMed  Google Scholar 

  56. Ishunina TA, Swaab DF . Alterations in the human brain in menopause. Maturitas 2007; 57: 20–22.

    CAS  PubMed  Google Scholar 

  57. Lavaque E, Sierra A, Azocoitia I, Garcia-Segura LM . Steroidogenic acute regulatory protein in the brain. Neuroscience 2006; 138: 741–747.

    CAS  PubMed  Google Scholar 

  58. Mani SK, Blaustein JD, O'Malley BW . Progesterone receptor function from a behavioral perspective. Horm Behav 1997; 31: 244–255.

    CAS  PubMed  Google Scholar 

  59. Segraves RT, Clayton A, Croft H, Wolf A, Warnock J . Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 25: 339–342.

    Google Scholar 

  60. Singh A, Kandimala G, Dewey Jr RB, O'Suilleabhain P . Risk factors for pathological gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 2007; 14: 1178–1181.

    CAS  PubMed  Google Scholar 

  61. Pfaus JG, Kippin TE, Centeno S . Conditioning and sexual behaviour: a review. Horm Behav 2001; 40: 291–321.

    CAS  PubMed  Google Scholar 

  62. Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR . Effect of estradiol vs. estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause 2006; 13: 528–537.

    PubMed  Google Scholar 

  63. Position statement. The role of local vaginal estrogen, the treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause 2007; 14: 357–369.

    Google Scholar 

  64. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2742–2751.

    CAS  PubMed  Google Scholar 

  65. Wang XN, Simmons HA, Saltto CT, Cosgrove PG, Thompson DD . Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause 2006; 13: 609–620.

    PubMed  Google Scholar 

  66. Davis SR, Mijland FA, Weijmar Schultz W . Tibolone vs. transdermal continuous combined estrogen plus progestin in the treatment of female sexual dysfunction in naturally menopausal women: results from the NETA trial. Maturitas 2006; 554S: S1–S112.

    Google Scholar 

  67. Organon International. FDA says tibolone not approvable as a menopause treatment in the US (press release), June 2, 2006. Amhem, The Netherlands:Organon International. www.organon.com/news/press_releases/tibolone_not_approvable.asp. Accessed November 2, 2007.

  68. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427.

    CAS  PubMed  Google Scholar 

  69. Cummings SR . LIFT study is discontinued. BMJ 2006; 332: 667.

    PubMed  PubMed Central  Google Scholar 

  70. Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Atherton PJ et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido: North Central Cancer Treatment Group Protocol N02C3. J Nat Cancer Inst 2007; 99: 672–679.

    CAS  PubMed  Google Scholar 

  71. Stevenson JC . HRT and the primary prevention of cardiovascular disease. Maturitas 2007; 57: 31–34.

    CAS  PubMed  Google Scholar 

  72. Hodis HN, Mack WJ . Postmenopausal hormonal therapy in clinical perspective. Menopause 2007; 14: 1–14.

    Google Scholar 

  73. Braunstein G, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual disorder in surgically menopausal women: a randomized, placeo-controlled trial. Arch Intern Med 2005; 165: 1582–1589.

    CAS  PubMed  Google Scholar 

  74. Buster JE, Kingsberg SA, Aguirre O, Breaux JG, Buch A, Rodenberg CA et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105: 944–952.

    CAS  PubMed  Google Scholar 

  75. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller SS . Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226–5233.

    CAS  PubMed  Google Scholar 

  76. Davis SR, van der Mooren MJ, van Lunsen RHW, Lopes P, Ribot J, Rees M et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo controlled-trial. Menopause 2006; 30: 387–396.

    Google Scholar 

  77. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM ONE STUDY. Menopause 2006; 13: 770–779.

    PubMed  Google Scholar 

  78. Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treatment of decreased sexual satisfaction in premenopausal women: a placebo-controlled randomized, dose ranging study. Annals Int Med 2008; 148: 569–577.

    Google Scholar 

  79. Schover LR . Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil Steril doi:10.1016/j.fertnstert.2007.05.057.

    PubMed  Google Scholar 

  80. Braunstein GD . Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007; 88: 1–17.

    CAS  PubMed  Google Scholar 

  81. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA . Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Int Med 2006; 166: 1483–1489.

    CAS  Google Scholar 

  82. Hofling M, Lindén Hirschberg A, Skoog L, Tani E, Hagerstrõm T, von Schoultz B . Teststerone inhibits estrogen/progesterone-induced breast cell proliferation in post menopausal women. Menopause 2007; 14: 183–190.

    PubMed  Google Scholar 

  83. Bell RJ, Davison SL, Papalie MA, McKenzie DP, Davis SR . Endogenous androgen levels and cardiovascular risk profile in women across the adult life. Menopause 2007; 14: 630–638.

    PubMed  Google Scholar 

  84. Wild RA . Endogenous androgens and cardiovascular risk. Menopause 2007; 14: 609–610.

    PubMed  Google Scholar 

  85. Zang H, Rydén M, Wåhlen K, Dahlman-Wright K, Arner P, Lindén Hirschberg A . Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of post menopausal women. Fertil Steril 2007; 88: 100–106.

    CAS  PubMed  Google Scholar 

  86. Davis SR, Walker KZ, Strauss BJG . Effects of estradiol with and without testosterone on body composition and relationships with lipids in post menopausal women. Menopause 2000; 7: 395–401.

    CAS  PubMed  Google Scholar 

  87. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W et al. Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J Clin Enocrinol Metab 2006; 91: 3697–3710.

    CAS  Google Scholar 

  88. The role of testosterone therapy in postmenopausal women: physicians' statement of the North American Menopause Society. Menopause 2005; 12: 497–511.

  89. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R . An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3: 626–683.

    Google Scholar 

  90. Safarinejad MR . Evaluation of safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled fixed dose randomized study. J Sex Med 2008; 5: 887–897.

    CAS  PubMed  Google Scholar 

  91. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S . Pharmacolgy of flibanserin. CNS Drug Rev 2002; 8: 117–142.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Kolasa T, Matulenko MA, Hakeem AA, Patel MV, Mortell K, Bhatia P et al. T-aryl-3(4-pyridene-2-ylpiperazin-1-yl)proan-1-one oximes as potent dopamine D4 receptor agonist for the treatment of erectile dysfunction. J Med Chem 2006; 49: 5093–5109.

    CAS  PubMed  Google Scholar 

  93. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL . A placebo-controlled trial of bupropion SR as an antidote for selective serotonin re-uptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65: 62–67.

    CAS  PubMed  Google Scholar 

  94. Segraves RT . Buproprion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 24: 339–342.

    CAS  PubMed  Google Scholar 

  95. Caruso S, Rugolo S', Agnello C, Intelisano G, DiMari L, Cianci A . Sildenafil improves sexual functioning in premenopausal women with Type I diabetes who are affected by sexual arousal disorder: double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006; 85: 1496–1501.

    CAS  PubMed  Google Scholar 

  96. Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD . Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171: 1189–1193.

    CAS  PubMed  Google Scholar 

  97. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N . Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal. J Women's Health Gend Based Med 2002; 11: 367–377.

    Google Scholar 

  98. Maw GN, Stobie A, Planken S, Pryde DC, Sanderson V, Platts MY et al. The structure of small molecule inhibitors of neutral endopeptidase. Structure–activity studies on functionalised glutaramides. Chem Biol Drug Des 2006; 67: 74–77.

    CAS  PubMed  Google Scholar 

  99. Ito TY, Polan ML, Whipple B, Trant AS . The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. J Sex Marital Ther 2006; 32: 369–378.

    PubMed  Google Scholar 

  100. Breit A, Wolff K, Kalwa H, Jarry H, Buch T, Gudermann T . The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors. J Biol Chem 2006; 281: 37447–37456.

    CAS  PubMed  Google Scholar 

  101. Cotreau MM, Chennathukuzhi VM, Harris HA, Han L, Dorner AJ, Apseloff G et al. A study of 17β-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas 2007; 58: 366–376.

    CAS  PubMed  Google Scholar 

  102. Brotto LA . Psychologic-based desire and arousal disorders: treatment strategies and outcome results. In: Goldstein, Meston, Davis, Traish (eds). Women's Sexual Function and Dysfunction. Taylor Francis: London, 2006, pp 441–448.

    Google Scholar 

  103. Perelman MA . Clinical application of CNS-acting agents in FSD. J Sex Med 2007; 4 (S4): 280–290.

    CAS  PubMed  Google Scholar 

  104. McCall KM, Meston CM . The effects of false positive and false negative physiological feedback on sexual arousal: a comparison of women with or without sexual arousal disorder. Arch Sex Behav 2007; 36: 518–530.

    PubMed  Google Scholar 

  105. Pukall C, Kandyba K, Amsel R, Khalife S, Binik Y . Effectiveness of hypnosis for the treatment of vulvar vestibulitis syndrome: a preliminary investigation. J Sex Med 2007; 4: 417–425.

    PubMed  Google Scholar 

  106. Bradford A, Meston C . Correlates of placebo response in the treatment of sexual dysfunction in women: a preliminary report. J Sex Med 2007; 4: 1345–1351.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. BC Centre for Sexual Medicine, Vancouver General Hospital, Vancouver, BC, Canada

    R Basson

Authors
  1. R Basson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Basson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basson, R. Women's sexual function and dysfunction: current uncertainties, future directions. Int J Impot Res 20, 466–478 (2008). https://doi.org/10.1038/ijir.2008.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.23

Keywords

This article is cited by

Search

Advanced search

Quick links